Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of prostate cancer
3.2.1.2 Technological advancement
3.2.1.3 Surging awareness and screening initiatives
3.2.1.4 Increasing popularity of prostate cancer diagnostic tests
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of skilled professionals
3.2.2.2 Stringent regulations
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Reimbursement scenario
3.7 Key market trends
3.8 Porter's analysis
3.9 PESTEL analysis
3.10 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Test Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Diagnostics tests
5.2.1 PSA
5.2.2 Prostate biopsy
5.2.3 Molecular/ genomic test
5.2.4 Other diagnostics tests
5.3 Imaging tests
5.3.1 Transrectal ultrasound (TRUS)
5.3.2 MRI
5.3.3 CT Scan
5.3.4 Other imaging tests
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Prostatic adenocarcinoma
6.3 Small cell carcinoma
6.4 Other prostate cancer types
Chapter 7 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Cancer research institutes
7.5 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Poland
8.3.7 Sweden
8.3.8 Netherlands
8.3.9 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Indonesia
8.4.7 Philippines
8.4.8 Vietnam
8.4.9 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Colombia
8.5.5 Chile
8.5.6 Peru
8.5.7 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Turkey
8.6.5 Iran
8.6.6 Israel
8.6.7 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Abbott Laboratories
9.2 AdvaCare Pharma
9.3 Beckman Coulter, Inc. (Danaher Corporation)
9.4 Becton, Dickinson and Company
9.5 BIOMÉRIEUX
9.6 F. Hoffmann-La Roche Ltd.
9.7 FUJIFILM Holdings Corporation
9.8 GE Healthcare Technologies Inc.
9.9 Glycanostcs Ltd.
9.10 Healgen
9.11 KOELIS
9.12 Koninklijke Philips N.V.
9.13 Metamark Genetics, Inc.
9.14 miR Scientific
9.15 Myriad Genetics, Inc.
9.16 Proteomedix
9.17 Siemens Healthineers AG
9.18 Veracyte
